US Oncology Therapeutics Market Report 2022 to 2030

US Oncology Therapeutics Market Analysis

$ 3999

The US oncology therapeutics market is projected to grow from $83 Bn in 2022 to $172 Bn by 2030, registering a CAGR of 9.6% during the forecast period of 2022-30. The development of new and innovative cancer treatments, such as immunotherapies and targeted therapies, is driving the growth of the oncology therapeutics market. This market is highly competitive, with many large pharmaceutical companies and biotech companies competing for market share. Some of the major players in the market include Roche, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, AstraZeneca, and Johnson & Johnson

ID: IN10USPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Shivam Zalke

Buy Now

US Oncology Therapeutics Market Executive Summary

The US oncology therapeutics market is projected to grow from $83 Bn in 2022 to $172 Bn by 2030, registering a CAGR of 9.6% during the forecast period of 2022-30.

Its market can be segmented into several categories based on the type of cancer, the type of therapy, and the distribution channel. The most common types of cancer treated in this market include breast cancer, lung cancer, prostate cancer, colorectal cancer, and leukemia.

The therapies used to treat these cancers can be broadly categorized into chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The chemotherapy segment is the largest segment of the market, but immunotherapy is the fastest-growing segment due to the high demand for more effective and less toxic treatments.

It is also segmented based on the distribution channel, including hospital pharmacies, retail pharmacies, and online pharmacies.

The market is highly competitive, with many large pharmaceutical companies and biotech companies competing for market share. Some of the major players in the market include Roche, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, AstraZeneca, and Johnson & Johnson.

US oncology therapeutics market analysis

Market Dynamics

The US oncology therapeutics market is driven by various factors, including:

Growing incidence of cancer: The US has one of the highest rates of cancer incidence in the world, with over 1.8 Mn new cases of cancer diagnosed each year. This increasing prevalence of cancer is driving the demand for oncology therapeutics.

Advancements in cancer research: The development of new and innovative cancer treatments, such as immunotherapies and targeted therapies, is driving the growth of the oncology therapeutics market. Ongoing research in the field of oncology is also leading to the development of new drugs and therapies that are more effective and have fewer side effects.

Aging population: The US population is aging, with a large number of baby boomers reaching retirement age. As people age, the risk of cancer increases, which is driving the demand for oncology therapeutics.

Favorable healthcare policies: The Affordable Care Act has expanded healthcare coverage and increased access to cancer treatments for many Americans. This has led to an increase in the demand for oncology therapeutics.

Increasing use of combination therapies: Combination therapies, which involve the use of multiple drugs or therapies to treat cancer, are becoming more common in the treatment of many types of cancer. This trend is driving the demand for oncology therapeutics.

Strong pipeline of new drugs: Many pharmaceutical companies are investing heavily in oncology research and development, which has led to a strong pipeline of new drugs and therapies for the treatment of cancer. This is expected to drive the growth of the oncology therapeutics market in the coming years.

Overall, its market is driven by a combination of demographic, scientific, and policy factors that are expected to continue driving growth in the market in the years to come.

Competitive Landscape

Key Players

The US oncology therapeutics market is highly competitive, with many key players competing for market share. Here are some of the key players in the US oncology therapeutics market:

Roche: Roche is a Swiss multinational healthcare company that develops and markets oncology therapeutics, including targeted therapies, immunotherapies, and chemotherapy drugs
Pfizer: Pfizer is a multinational pharmaceutical company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs
Merck: Merck is a multinational pharmaceutical company that develops and markets oncology therapeutics, including immunotherapies, targeted therapies, and chemotherapy drugs
Bristol-Myers Squibb: Bristol-Myers Squibb is a multinational pharmaceutical company that develops and markets oncology therapeutics, including immunotherapies and targeted therapies
Novartis: Novartis is a Swiss multinational healthcare company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs
Amgen: Amgen is a biotechnology company that develops and markets oncology therapeutics, including immunotherapies and targeted therapies
AstraZeneca: AstraZeneca is a multinational pharmaceutical company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs
AbbVie: AbbVie is a biopharmaceutical company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs
Eli Lilly and Company: Eli Lilly and Company is a multinational pharmaceutical company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs
Johnson & Johnson: Johnson & Johnson is a multinational healthcare company that develops and markets oncology therapeutics, including targeted therapies and chemotherapy drugs

Overall, these key players are focused on developing and commercializing innovative cancer treatments, including immunotherapies, targeted therapies, and combination therapies, with the aim of improving patient outcomes and capturing market share.

Healthcare Policies and Regulatory Landscape

The US oncology therapeutics market is regulated by a number of healthcare policies and regulations aimed at ensuring the safety and efficacy of cancer treatments.

Here are some key policies and regulations that impact its market:

Food and Drug Administration (FDA): The FDA is responsible for regulating the development, approval, and marketing of drugs and medical devices, including oncology therapeutics. The FDA reviews clinical trial data and approves new drugs for use in the US market based on their safety and efficacy.

Medicare: Medicare is a federal health insurance program that covers the cost of healthcare services for eligible individuals aged 65 and over, as well as people with certain disabilities. Medicare covers many cancer treatments, including chemotherapy and radiation therapy.

Affordable Care Act (ACA): The ACA has expanded healthcare coverage and increased access to cancer treatments for many Americans. The law includes provisions that require health insurance plans to cover cancer screening tests and treatments, and it prohibits insurers from denying coverage to people with pre-existing conditions, including cancer.

National Cancer Institute (NCI): The NCI is a federal agency that conducts and supports cancer research, training, and education. The NCI provides funding for research on new cancer treatments, as well as clinical trials to test the safety and efficacy of new drugs and therapies.

Centers for Medicare and Medicaid Services (CMS): The CMS is responsible for administering the Medicare and Medicaid programs, as well as implementing regulations related to healthcare reimbursement. The CMS sets reimbursement rates for cancer treatments and implements policies related to value-based care, which aims to improve patient outcomes while reducing healthcare costs.

Overall, the US oncology therapeutics market is heavily regulated, with numerous policies and regulations in place to ensure the safety and efficacy of cancer treatments. These policies and regulations are aimed at improving patient outcomes and increasing access to cancer care, while also controlling healthcare costs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Market Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.